Changes in Hong Kong stocks | CRO concept stocks have the highest gains, the mid-term report continues to verify the high boom in the industry, and many companies improve their performance guidelines

The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Gloria Ying (06821) rose 5.89% to HK$142.1; Kanglong Chemical (03759) rose 4.72% to HK$28.84; Tiger Pharmaceuticals (03347) rose 4.64% to HK$43.32; and Pharmaceutical Biotech (02269) rose 2.30% to HK$48.08.

According to the news, the interim results of domestic and foreign CXO companies continue to verify the high prosperity of the industry. Guojin Securities said that recently, various overseas CXO companies have successively released their 2026 interim reports. Overall, all companies' orders for the second quarter have improved markedly, pre-clinical book-to-bill indicators have improved markedly, and most companies have revised their performance guidelines. China Pharmaceutical Kangde released an interim report. The results greatly exceeded market expectations, and at the same time, the annual performance guidelines were drastically raised.

Goldman Sachs published a research report saying that the results for the second quarter and first half of this year reflect that China's CRO/CDMO industry is clearly recovering, corporate profits have exceeded expectations, and upward guidelines and orders are strong. The bank said it is optimistic about Pharmaceuticals, Kanglong Chemical, Gloria, Tiger Pharmaceuticals, and Kingsley.